AI assistant
Altimmune, Inc. — Director's Dealing 2010
Nov 5, 2010
33207_dirs_2010-11-05_d1b723e1-9198-4daa-bab6-52df16f02d17.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PHARMATHENE, INC (PIP)
CIK: 0001326190
Period of Report: 2010-11-03
Reporting Person: HEALTHCARE VENTURES VII LP (10% Owner)
Reporting Person: LAWLOR AUGUSTINE (10% Owner)
Reporting Person: LITTLECHILD JOHN W (10% Owner)
Reporting Person: Mirabelli Christopher (10% Owner)
Reporting Person: WERNER HAROLD R (10% Owner)
Reporting Person: CAVANAUGH JAMES H (Director, 10% Owner)
Reporting Person: HealthCare Partners VII, L.P. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2010-11-03 | Common Stock | C | 935814 | $2.5417 | Acquired | 4253057 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2010-11-03 | 10% Convertible Note | $2.5417 | C | 935814 | Disposed | 2011-07-28 | Common Stock (935814) | Indirect |
Footnotes
F1: These securities are owned by HealthCare Ventures VII, L.P. ("HCVVII"). These securities are indirectly owned by HealthCare Partners VII, L.P. ("HCPVII"), the General Partner of HCVVII and each of James Cavanaugh, Harold Werner, John Littlechild, Christopher Mirabelli and Augustine Lawlor, the general partners of HCPVII. Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor disclaim beneficial ownership of those securities in which they do not have a pecuniary interest and this report shall not be deemd an admission that they are the beneficial owners of these securities for purposes of Section 16. In addition, James Cavanaugh is a Director of the Issuer.
F2: The 10% Convertible Note (the "Note") together with accrued interest was convertible into the Issuer's Common Stock at a price of $2.541667 per share. The total number of shares acquired includes 829,173 shares of Common Stock underlying the Note together with 106,641 shares of Common Stock representing accrued interest under the Note.
F3: Immediately.
F4: This Note together with a Warrant was received pursuant to a Note and Warrant Purchase Agreement dated as of July 24, 2009, as amended on July 26, 2009 and July 28, 2009, by and among the Issuer and certain noteholders, all as more specifically reported on Form 4 filed with the Securities & Exchange Commission on July 30, 2009.